Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ARS Pharmaceuticals (SPRY – Research Report), AnaptysBio (ANAB – Research Report) and Allakos (ALLK – Research Report).
ARS Pharmaceuticals (SPRY)
Leerink Partners analyst Roanna Ruiz maintained a Buy rating on ARS Pharmaceuticals on May 9 and set a price target of $19.00. The company’s shares closed last Monday at $8.89.
According to TipRanks.com, Ruiz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on ARS Pharmaceuticals is a Strong Buy with an average price target of $19.00.
See the top stocks recommended by analysts >>
AnaptysBio (ANAB)
Leerink Partners analyst David Risinger maintained a Buy rating on AnaptysBio on May 10 and set a price target of $47.00. The company’s shares closed last Monday at $23.99.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
AnaptysBio has an analyst consensus of Strong Buy, with a price target consensus of $50.00, representing an 113.1% upside. In a report issued on May 9, Wells Fargo also maintained a Buy rating on the stock with a $56.00 price target.
Allakos (ALLK)
In a report issued on May 9, Thomas Smith from Leerink Partners reiterated a Hold rating on Allakos, with a price target of $2.00. The company’s shares closed last Monday at $1.22, close to its 52-week low of $0.98.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Currently, the analyst consensus on Allakos is a Hold with an average price target of $3.25, representing a 164.2% upside. In a report issued on May 10, LifeSci Capital also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SPRY:
- ARS Pharmaceuticals Unveils Updated Corporate Presentation
- ARS Pharmaceuticals submits response for neffy MA, partners with CSL Seqirus
- ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
- Insider Trading: ARS Pharmaceuticals’ (NASDAQ:SPRY) Insiders Buy Shares Worth $679K
- ARS Pharmaceuticals submits response to FDA’s CRL for neffy nasal spray
